Deharo P, Bisson A, Herbert J, et al. - Researchers assessed the results of transcatheter aortic valve replacement (TAVR) according to Sapien 3 balloon-expandable (BE) vs Evolut R self-expanding TAVR technology at a nationwide level in France, using the French administrative hospital-discharge database. Overall 31,113 patients managed with either Sapien 3 BE or Evolut R self-expanding TAVR were identified. Following matching on baseline features, there remained 20,918 patients (10,459 in each group with BE or self-expanding valves). Based on the largest cohort available, the findings revealed lower rates of all-cause mortality, cardiovascular mortality, rehospitalization for heart failure, and pacemaker implantation following a TAVR procedure in relation to the use of Sapien 3 BE valves.